Bahrain’s early rollout of Paxlovid, an antiviral medication offered free to high-risk patients during the Covid-19 pandemic, helped keep hospital admissions low during its later waves, reducing the odds of hospitalisation by nearly 40 per cent among those who took the drug, according to a recent study.
This is among the key findings of the peer-reviewed study titled ‘A Retrospective Observational Study on Covid‑19 Patients Receiving Treatment with Nirmatrelvir/Ritonavir (Paxlovid)’ conducted by a group of researchers from the Royal College of Surgeons in Ireland – Medical University of Bahrain (RCSI Bahrain), Salmaniya Medical Complex (SMC), Primary Healthcare Centres (PHC), Bahrain Defence Force (BDF) Hospital and Pfizer .
&uuid=(email))